Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A

Blood

Volumn 107, Issue 8, 2006, Pages 3167-3172

  Astermark, Jan ^a   Oldenburg, Johannes ^b   Pavlova, Anna ^b   Berntorp, Erik ^b   Lefvert, Ann Kari ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; MICROSATELLITE DNA; TAQ POLYMERASE;

ADULT; AGED; ALLELE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CHROMOSOME INVERSION; CHROMOSOME NOR; CONFIDENCE INTERVAL; DISEASE SEVERITY; DNA POLYMORPHISM; EXON; FAMILY; FAMILY HISTORY; GENE MUTATION; GENETIC ASSOCIATION; HEMOPHILIA A; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PATIENT; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33645751563     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3918     Document Type: Article

References (31)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418-435.
2. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol. 2004;127:379-391.
3. Astermark J. Treatment of the bleeding inhibitor patient. Semin Thromb Hemost. 2003;29:77-86.
4. DiMichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia. 2004;10(suppl 4):140-145.
5. Vermylen J. How do some haemophiliacs develop inhibitors? Haemophilia. 1998;4:538-542.
6. Oldenburg J, Schröder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004;41(suppl 1):82-88.
7. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost. 1999;82:500-504.
8. Astermark J, Berntorp E, White GC, Kroner BL, and the MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7:267-272.
9. Schwaab R, Brackman HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402-1406.
10. Tuddenhamn EGD, Mcvey JH. Genetic basis of inhibitor development in haemophilia A. Haemophilia. 1998;4:543-545.
11. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia. 2002;8(suppl 2):23-29.
12. Goodeve A. Genetic determinants of inhibitor formation in patients with hemophilia. Haematologica. 2003;88(suppl 12):2-3.
13. Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E, and the MIBS Study Group. The Malmo International Brother Study (MIBS): genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005;90:924-931.
14. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A Taq 1 polymorphism in the human interleukin 1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur J Clin Invest. 1992;22:396-402.
15. Pociot F, Ronningen KS, Bergholdt R, et al. The Danish Study Group of Diabetes in Childhood: genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes - evidence for polygenicity in man. Autoimmunity. 1992;19:169-178.
16. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20(suppl 27): S1-S13.
17. Bioque G, Crusius JB, Koutroubakis I, et al. Allelic polymorphism in IL-1β and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol. 1995;102:379-383.
18. Huang D, Pirskanen R, Hjelmstrom P, Lefvert AK. Polymorphisms in IL-1β and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol. 1998;81:76-81.
19. Rosenwasser LJ. Promoter polymorphism in the candidate genes, IL-4, IL-9, TGF-beta1, for atopy and asthma. Int Arch Allergy Immunol. 1999;118:268-270.
20. Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995;181:839-844.
21. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 1995;4:393-395.
22. Zhou Y, Giscombe R, Huang D, Lefvert AK. Novel genetic association of Wegener's granulomatosis to the interleukin-10 gene. J Rheumatol. 2002;29:317-320.
23. Huang D, Zhou Y, Xia SQ, Pirskanen R, Liu L, Lefvert AK. Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: implications on diverse effects of IL-10 in the pathogenesis of the disease. J Neuroimmunol. 1999;94:82-87.
24. Zheng C, Huang D, Liu L, et al. Interleukin-10 gene promoter polymorphisms in the multiple myeloma. Int J Cancer. 2001;95:184-188.
25. White GC II, Rosendaal F, Aledort LM, et al. Defi-nitions in hemophilia: recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.
26. Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost. 2001;85:577-579.
27. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh. 1975;34:869-872.
28. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247-251.
29. Noguchi E, Shibasaki M, Arinami T, et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy. 1998;28:449-453.
30. Eskdale J, Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics. 1995;42:444-445.
31. Lozier JN, Tayebi N, Zhang P. Mapping of genes that control the antibody response to human factor IX in mice. Blood. 2005;105:1029-1035.